Cochrane · systematic review · CD010854
Add‐back therapy with GnRH analogues for uterine fibroids
Moroni, RM, Martins, WP, Ferriani, RA, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
31
current version
GRADE rated
16
No studies
14
Included studies
NR
No studies 14 · 45.2%Ungraded 1 · 3.2%Very low 1 · 3.2%Low 13 · 41.9%Moderate 2 · 6.5%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
GnRH‐a + medroxyprogesterone acetate compared to GnRH‐a ± placebo for uterine fibroids
Population: patients with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Bone density (SMD) ‐ GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo | no estimate extracted | 1 study · 16 participants | Low Downgraded: imprecision |
Uterine size (cm3) ‐ GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo | no estimate extracted | 2 studies · 32 participants | Low Downgraded: imprecision |
Uterine bleeding GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Severity of vasomotor symptoms GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Rate of vasomotor symptoms ‐ GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placebo | RR 0.13 [0.02, 0.84] | 1 study · 16 participants | Low Downgraded: imprecision |
GnRH‐a + tibolone compared to GnRH‐a ± placebo for uterine fibroids
Population: patients with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life (SMD) ‐ GnRH‐a + tibolone vs GnRH‐a ± placebo | no estimate extracted | 1 study · 110 participants | Low Downgraded: imprecision |
Bone density (SMD) ‐ GnRH‐a + tibolone vs GnRH‐a ± placebo | no estimate extracted | 3 studies · 160 participants | Moderate Downgraded: imprecision |
Uterine size (cm3) ‐ GnRH‐a + tibolone vs GnRH‐a ± placebo | no estimate extracted | 6 studies · 365 participants | Moderate Downgraded: imprecision |
Uterine bleeding GnRH‐a + tibolone vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Severity of vasomotor symptoms (SMD) ‐ GnRH‐a + tibolone vs GnRH‐a ± placebo | no estimate extracted | 4 studies · 268 participants | Ungraded |
Rate of vasomotor symptoms ‐ GnRH‐a + tibolone vs GnRH‐a ± placebo | RR 0.38 [0.14, 1.02] | 1 study · 20 participants | Low Downgraded: imprecision |
GnRH‐a + raloxifene compared to GnRH‐a ± placebo for uterine fibroids
Population: patients with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life (SMD) ‐ GnRH‐a + raloxifene vs GnRH‐a ± placebo | no estimate extracted | 1 study · 74 participants | Low Downgraded: imprecision |
Bone density (SMD) ‐ GnRH‐a + raloxifene vs GnRH‐a ± placebo | no estimate extracted | 1 study · 91 participants | Low Downgraded: imprecision |
Uterine size (cm3) ‐ GnRH‐a + raloxifene vs GnRH‐a ± placebo | no estimate extracted | 1 study · 91 participants | Low Downgraded: imprecision |
Uterine bleeding (VAS) ‐ GnRH‐a + raloxifene vs GnRH‐a ± placebo | no estimate extracted | 1 study · 91 participants | Low Downgraded: imprecision |
Severity of vasomotor symptoms (no. of hot flushes per day) ‐ GnRH‐a + raloxifene vs GnRH‐a ± placebo | no estimate extracted | 1 study · 91 participants | Low Downgraded: imprecision |
Rate of vasomotor symptoms GnRH‐a + raloxifene vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
GnRH‐a + estriol compared to GnRH‐a ± placebo for uterine fibroids
Population: patients with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life GnRH‐a + estriol vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Bone density (SMD) ‐ GnRH‐a + estriol vs GnRH‐a ± placebo | no estimate extracted | 1 study · 12 participants | Low Downgraded: imprecision |
Uterine Size GnRH‐a + estriol vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Uterine bleeding GnRH‐a + estriol vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Severity of vasomotor symptoms GnRH‐a + estriol vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Rate of vasomotor symptoms GnRH‐a + estriol vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
GnRH‐a + ipriflavone compared to GnRH‐a ± placebo for uterine fibroids
Population: patients with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life GnRH‐a + ipriflavone vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Bone density (SMD) ‐ GnRH‐a + ipriflavone vs GnRH‐a ± placebo | no estimate extracted | 1 study · 95 participants | Low Downgraded: imprecision |
Uterine size GnRH‐a + ipriflavone vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Uterine bleeding GnRH‐a + ipriflavone vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Severity of vasomotor symptoms GnRH‐a + ipriflavone vs GnRH‐a ± placebo | no estimate extracted | NR | No studies |
Rate of vasomotor symptoms ‐ GnRH‐a + ipriflavone vs GnRH‐a ± placebo | RR 0.67 [0.44, 1.02] | 1 study · 95 participants | Low Downgraded: imprecision |
GnRH‐a + conjugated estrogens compared to GnRH‐a ± placebo for uterine fibroids
Population: women with uterine fibroids
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Reduction in uterine size GnRH‐a + conjugated estrogens vs GnRH‐a ± placebo | no estimate extracted | 1 study · 27 participants | Very low Downgraded: risk of bias, imprecision |